Business Context and Reporting Period
This Form 8-K, filed on December 14, 2020, by Aptevo Therapeutics Inc. (APVO), addresses retrospective revisions to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019. The filing recasts historical financial information to reflect the sale of the Aptevo BioTherapeutics Business (including the IXINITY product and Hemophilia B business) to Medexus Pharma, Inc., which closed on February 28, 2020. Additionally, the filing retroactively adjusts all share and per share amounts to reflect a 1-for-14 reverse stock split effected on March 26, 2020.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it serves as a notice that the Aptevo BioTherapeutics Business is now presented as a discontinued operation and held for sale in the recast financial statements. The filing clarifies that the original 2019 Form 10-K is not being amended or restated, but rather specific portions are being recast in Exhibit 99.1 to align with the discontinued operations classification and the reverse stock split.
Material Changes Versus Prior Period
- Discontinued Operations: The Aptevo BioTherapeutics Business is now classified as discontinued operations and held for sale for all periods presented in the recast 2019 financials, whereas it was previously reported as a continuing operation.
- Share Count Adjustments: All share and per share amounts in the historical data have been retroactively adjusted to reflect the 1-for-14 reverse stock split.
- Segment Reporting: The measure of profit or loss and reportable segments have been adjusted to exclude the sold business.
Guidance, Outlook, and Risks
The filing does not contain new forward-looking guidance, management commentary on future operations, or specific risk factors beyond the context of the transaction. It explicitly states that the recast information does not reflect events occurring after the filing of the original 2019 Form 10-K. Investors are directed to read Exhibit 99.1 in conjunction with other subsequent SEC filings for updated information.
Key Facts for Investor Verification
- Verify the specific financial impact of the discontinued operations by reviewing Exhibit 99.1 attached to this filing.
- Confirm that all historical per-share metrics in the 2019 10-K have been adjusted for the 1-for-14 reverse stock split.
- Note that this filing is a recast of presentation only and does not constitute a restatement of the audited consolidated financial statements.
- Review subsequent filings (e.g., 10-Q for the quarter ended March 31, 2020) for the initial presentation of the business as held for sale.